# BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

> **NCT04669262** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BGB-DXP604
- **DRUG:** BGB-DXP593
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04669262
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2021-05-21
- **Final completion:** 2021-05-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04669262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04669262, "BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04669262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*